Selank regulatory status in 2026
A plain-English look at where Selank stands with the FDA in 2026.
TL;DR
- Selank is not FDA (Food and Drug Administration)-approved. FDA removed it from the Category 2 list on September 27, 2024, after the nomination was withdrawn.
- As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list. Selank was not on the agenda of FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting.
- In February 2026, HHS (Department of Health and Human Services) Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
Selank regulatory status: what it is
Selank is a synthetic peptide developed by Russian researchers, studied mainly for anxiety-related effects. It is not an FDA-approved medication. In the U.S. compounding system, FDA placed it in Category 2 in 2023 and removed it on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, it is not in any FDA 503A category. It is not on the bulk drug substances list under Section 503A (the section of federal law covering pharmacy compounding for individual patients).
How it works
Think of Category 2 like a "hold" shelf at a pharmacy warehouse. The substance isn't destroyed or banned outright — it's set aside pending more safety review. Selank was on that hold shelf from 2023 until FDA removed it on September 27, 2024.
Who asks about it
People researching nootropic or anti-anxiety peptides often find Selank mentioned alongside Semax. They want to know if it's legal, if a physician can prescribe it, and whether the 2026 headlines about peptide reclassification apply to it specifically.
What the research says
Selank's evidence base is largely Russian, not Western. A 2008 study compared Selank to medazepam in 62 patients with generalized anxiety disorder and neurasthenia (PubMed, 2008). A 2014 study compared Selank to phenazepam in 60 patients with phobic-anxiety disorders. These are real human studies. But they are small, Russian-language, and fall short of the evidence the FDA requires for approval.
What to know before considering it
FDA removed Selank from Category 2 on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list. Selank was not on the agenda of FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
The Halftime POV
We explain the regulatory picture plainly rather than promise access.
Related reading:
- Why some peptides are still Category 2
- What Category 2 status means for TB-500, KPV, DSIP, and Epithalon in 2026
- The PCAC advisory committee: who decides which peptides are accessible
- Category 2 patient risk
FAQ
Q: Is Selank FDA-approved? A: No. Selank is not FDA (Food and Drug Administration)-approved for any use in the United States. FDA removed Selank from Category 2 on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list.
Q: What does Category 2 mean for Selank? A: Category 2 is FDA's list of bulk drug substances that raise significant safety risks. Selank was on that list from 2023 until FDA removed it on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list.
Q: Can you get Selank from a compounding pharmacy in 2026? A: FDA removed Selank from Category 2 on September 27, 2024. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list. Selank was not on the agenda of FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. In February 2026, HHS (Department of Health and Human Services) Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
Q: Is Selank's research based on human studies? A: Most Selank research comes from Russian institutions, including small human trials of around 60 to 120 patients for anxiety-related conditions. Western, FDA-standard clinical trials have not been completed.
Disclaimer
Selank was previously in FDA's Category 2. FDA removed it from Category 2 on September 27, 2024. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
Frequently asked questions
Is Selank FDA-approved?
No. Selank is not FDA (Food and Drug Administration)-approved for any use in the United States. FDA removed Selank from Category 2 on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list.
What does Category 2 mean for Selank?
Category 2 is FDA's list of bulk drug substances that raise significant safety risks. Selank was on that list from 2023 until FDA removed it on September 27, 2024, after the nomination was withdrawn. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list.
Can you get Selank from a compounding pharmacy in 2026?
FDA removed Selank from Category 2 on September 27, 2024. As of September 14, 2026, Selank is not in any FDA 503A category and is not on the 503A bulks list. Selank was not on the agenda of FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. In February 2026, HHS (Department of Health and Human Services) Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
Is Selank's research based on human studies?
Most Selank research comes from Russian institutions, including small human trials of around 60 to 120 patients for anxiety-related conditions. Western, FDA-standard clinical trials have not been completed.
Keep reading
Every protocol is reviewed by a licensed physician and filled by a licensed 503A compounding pharmacy.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.